What is Morphle Labs?
Morphle Labs Inc. operates at the intersection of advanced robotics and artificial intelligence, providing specialized solutions for digital pathology. The company's core product suite, which includes the Robotome microtome and MorphoLens slide scanners, addresses critical bottlenecks in cancer diagnostics. By automating the preparation and digitization of tissue samples, Morphle Labs enables healthcare providers and research institutions to transition from traditional, manual workflows to high-efficiency, AI-augmented telepathology. Their market position is defined by a commitment to seamless integration, offering robust support systems that facilitate the adoption of digital slide storage and remote diagnostic capabilities in complex clinical environments.
How much funding has Morphle Labs raised?
Morphle Labs has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2025): $5M with participation from Inflexor
Key Investors in Morphle Labs
Inflexor
Inflexor Ventures is a technology-focused venture capital firm that invests in next-generation tech startups led by innovative founding teams. The firm provides capital and strategic guidance to foster groundbreaking ideas in science and engineering.
What's next for Morphle Labs?
With this major enterprise-level funding, Morphle Labs is expected to scale its manufacturing capabilities and expand its footprint in the international telepathology market. The strategic roadmap likely involves deepening the integration of its AI-enabled diagnostic algorithms to improve accuracy and turnaround times for pathology labs. As the company moves beyond its initial growth phase, the focus will shift toward establishing long-term partnerships with major hospital systems and research centers, effectively cementing its role as a foundational technology provider in the digital transformation of oncology and diagnostic medicine.
See full Morphle Labs company page
